# Chiara Baldini

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 152 papers | 4,019 citations | 35 h-index | 58 g-index |
| 168 ext. papers | 4,974 ext. citations | 4.5 avg, IF | 5.21 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 152 | Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.. *Computational and Structural Biotechnology Journal*, **2022**, 20, 471-484 | 6.8 | 0 |
| 151 | Classification Criteria in Sjögren's Syndrome **2022**, 29-35 | | |
| 150 | Myeloid neoplasms and autoimmune diseases: markers of association. *Clinical and Experimental Rheumatology*, **2022**, 40, 49-55 | 2.2 | 1 |
| 149 | Systemic vasculitis: one year in review 2022.. *Clinical and Experimental Rheumatology*, **2022**, 40, 673-687 | 2.2 | |
| 148 | A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. *Diagnostics*, **2022**, 12, 1139 | 3.8 | 3 |
| 147 | Salivary Proteomics Markers for Preclinical Sjögren's Syndrome: A Pilot Study. *Biomolecules*, **2022**, 12, 738 | 5.9 | 1 |
| 146 | SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. *Rheumatology*, **2021**, 60, 2946-2957 | 3.9 | 8 |
| 145 | Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. *Frontiers in Immunology*, **2021**, 12, 615656 | 8.4 | 1 |
| 144 | Characterization of Extracellular Vesicle Cargo in Sjögren's Syndrome through a SWATH-MS Proteomics Approach. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 3 |
| 143 | A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. *Journal of Autoimmunity*, **2021**, 121, 102648 | 15.5 | 7 |
| 142 | Comorbidities (excluding lymphoma) in Sjögren's syndrome. *Rheumatology*, **2021**, 60, 2075-2084 | 3.9 | 16 |
| 141 | Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. *Rheumatology*, **2021**, 60, 4558-4567 | 3.9 | 4 |
| 140 | Ultra-high frequency ultrasonography (UHFUS)-guided minor salivary gland biopsy: A promising procedure to optimize labial salivary gland biopsy in Sjögren's syndrome. *Journal of Oral Pathology and Medicine*, **2021**, 50, 485-491 | 3.3 | 3 |
| 139 | Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. *Drugs and Aging*, **2021**, 38, 265-284 | 4.7 | 0 |
| 138 | Unraveling Human AQP5-PIP Molecular Interaction and Effect on AQP5 Salivary Glands Localization in SS Patients. *Cells*, **2021**, 10, | 7.9 | 5 |
| 137 | The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. *European Heart Journal*, **2021**, 42, 4389-4400 | 9.5 | 10 |
| 136 | Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. *Arthritis and Rheumatology*, **2021**, 74, 295 | 9.5 | 5 |

| | | | |
|---|---|---|---|
| 135 | Ezrin Is a Novel Protein Partner of Aquaporin-5 in Human Salivary Glands and Shows Altered Expression and Cellular Localization in Sjögren's Syndrome. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 4 |
| 134 | Myeloid neoplasms and autoimmune diseases: markers of association. *Clinical and Experimental Rheumatology*, **2021**, | 2.2 | 3 |
| 133 | COVID-19: the new challenge for rheumatologists. One year later. *Clinical and Experimental Rheumatology*, **2021**, 39, 203-213 | 2.2 | 1 |
| 132 | One year in review 2021: systemic vasculitis. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 129, 3-12 | 2.2 | 1 |
| 131 | One year in review 2021: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2021**, | 2.2 | 3 |
| 130 | One year in review 2021: systemic vasculitis. *Clinical and Experimental Rheumatology*, **2021**, 39, 3-12 | 2.2 | 1 |
| 129 | Combined seronegativity in Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2021**, 39, 80-84 | 2.2 | 1 |
| 128 | One year in review 2021: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2021**, 39, 3-13 | 2.2 | 2 |
| 127 | Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. *Clinical and Experimental Rheumatology*, **2021**, 39, 166-174 | 2.2 | 0 |
| 126 | Patient-reported experience and health-related quality of life in patients with primary Sjögren's syndrome in Europe. *Clinical and Experimental Rheumatology*, **2021**, 39, 123-130 | 2.2 | |
| 125 | COVID-19: the new challenge for rheumatologists. One year later. *Clinical and Experimental Rheumatology*, **2021**, 39, 203-213 | 2.2 | 2 |
| 124 | Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 133, 166-174 | 2.2 | |
| 123 | Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. *Frontiers in Immunology*, **2020**, 11, 594096 | 8.4 | 17 |
| 122 | The CoV-2 outbreak: how hematologists could help to fight Covid-19. *Pharmacological Research*, **2020**, 157, 104866 | 10.2 | 25 |
| 121 | Ultra-high frequency ultrasound (UHFUS) applications in Sjogren syndrome: narrative review and current concepts. *Gland Surgery*, **2020**, 9, 2248-2259 | 2.2 | 5 |
| 120 | Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. *Rheumatology*, **2020**, 59, 2350-2359 | 3.9 | 24 |
| 119 | Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjögren's syndrome: A systematic review from the Italian Society of Rheumatology. *Autoimmunity Reviews*, **2020**, 19, 102447 | 13.6 | 35 |
| 118 | Fitness for purpose of routinely recorded health data to identify patients with complex diseases: The case of Sjögren's syndrome. *Learning Health Systems*, **2020**, 4, e10242 | 3 | 1 |

| | | | |
|---|---|---|---|
| 117 | Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. *Frontiers in Oncology*, **2020**, 10, 1428 | 5.3 | 22 |
| 116 | Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. *Annals of the Rheumatic Diseases*, **2020**, 79, 1588-1599 | 24 | 38 |
| 115 | Sjögren's Syndrome: The Clinical Spectrum of Male Patients. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 15 |
| 114 | One year in review 2020: vasculitis. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 124, 3-14 | 2.2 | 1 |
| 113 | One year in review 2020: pathogenesis of primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 3-9 | 2.2 | 7 |
| 112 | The use of digital image analysis in the histological assessment of Sjögren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 180-188 | 2.2 | 4 |
| 111 | Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 53-56 | 2.2 | |
| 110 | Ultra-high frequency ultrasonography of labial glands is a highly sensitive tool for the diagnosis of Sjögren's syndrome: a preliminary study. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 210-215 | 2.2 | 2 |
| 109 | Total area of inflammatory infiltrate and percentage of inflammatory infiltrate identify different clinical-serological subsets of primary Sjögren's syndrome better than traditional histopathological parameters. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 195-202 | 2.2 | 3 |
| 108 | Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 85-94 | 2.2 | 1 |
| 107 | Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 189-194 | 2.2 | |
| 106 | Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 9 |
| 105 | MicroRNA-mediated Regulation of Mucin-type O-glycosylation Pathway: A Putative Mechanism of Salivary Gland Dysfunction in Sjögren Syndrome. *Journal of Rheumatology*, **2019**, 46, 1485-1494 | 4.1 | 7 |
| 104 | The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. *Frontiers in Oncology*, **2019**, 9, 532 | 5.3 | 10 |
| 103 | Phenotyping multiple subsets in Sjögren's syndrome: a salivary proteomic SWATH-MS approach towards precision medicine. *Clinical Proteomics*, **2019**, 16, 26 | 5 | 15 |
| 102 | Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. *RMD Open*, **2019**, 5, e001064 | 5.9 | 24 |
| 101 | Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. *Nature Communications*, **2019**, 10, 5120 | 17.4 | 71 |
| 100 | One year in review 2019: vasculitis. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 117, 3-19 | 2.2 | 3 |

| | | | |
|---|---|---|---|
| 99 | Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 97-106 | 2.2 | 4 |
| 98 | Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 114-122 | 2.2 | 16 |
| 97 | One year in review 2019: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 3-15 | 2.2 | 13 |
| 96 | Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 133-139 | 2.2 | 1 |
| 95 | Salivary extracellular vesicles versus whole saliva: new perspectives for the identification of proteomic biomarkers in Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 240-248 | 2.2 | 6 |
| 94 | Biomarkers for Sjögren's syndrome. *Biomarkers in Medicine*, **2018**, 12, 275-286 | 2.3 | 31 |
| 93 | Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. *International Archives of Allergy and Immunology*, **2018**, 175, 61-69 | 3.7 | 15 |
| 92 | The Association of Sjögren Syndrome and Autoimmune Thyroid Disorders. *Frontiers in Endocrinology*, **2018**, 9, 121 | 5.7 | 17 |
| 91 | Sjögren's syndrome: state of the art on clinical practice guidelines. *RMD Open*, **2018**, 4, e000789 | 5.9 | 16 |
| 90 | One year in review 2018: systemic vasculitis. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 111, 12-32 | 2.2 | 7 |
| 89 | One year in review 2018: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 14-26 | 2.2 | 10 |
| 88 | How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 102-112 | 2.2 | 34 |
| 87 | A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 145-149 | 2.2 | 2 |
| 86 | Imaging in primary Sjögren's syndrome: the 'obsolete and the new'. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 215-221 | 2.2 | 11 |
| 85 | Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 137-144 | 2.2 | 5 |
| 84 | Advances in salivary gland ultrasonography in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 114, 159-164 | 2.2 | 10 |
| 83 | Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. *Annals of the Rheumatic Diseases*, **2017**, 76, 1042-1050 | 2.4 | 73 |
| 82 | Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. *Journal of Rheumatology*, **2017**, 44, 1179-1183 | 4.1 | 24 |

| | | | |
|---|---|---|---|
| 81 | Systemic vasculitis and the lung. *Current Opinion in Rheumatology*, **2017**, 29, 45-50 | 5.3 | 4 |
| 80 | Updates on Sjögren's syndrome: from proteomics to protein biomarkers. *Expert Review of Proteomics*, **2017**, 14, 491-498 | 4.2 | 10 |
| 79 | Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjögren's syndrome. *Rheumatology*, **2017**, 56, 1031-1038 | 3.9 | 19 |
| 78 | Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literature. *Rheumatology International*, **2017**, 37, 2115-2121 | 3.6 | 8 |
| 77 | Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. *RMD Open*, **2017**, 3, e000364 | 5.9 | 64 |
| 76 | International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?. The unmet needs and the clinical grey zone in autoimmune disease management. | 13.6 | 84 |
| 75 | Difference in clinical presentation between women and men in incident primary Sjögren's syndrome. *Biology of Sex Differences*, **2017**, 8, 16 | 9.3 | 18 |
| 74 | Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2017**, 35, 546-547 | 2.2 | 3 |
| 73 | One year in review 2017: primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2017**, 35, 179-191 | 2.2 | 35 |
| 72 | One year in review 2017: systemic vasculitis. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 103, 5-26 | 2.2 | 3 |
| 71 | Development of de novo major involvement during follow-up in Behçet's syndrome. *Clinical Rheumatology*, **2016**, 35, 247-50 | 3.9 | 8 |
| 70 | Major Salivary Gland Ultrasonography in the Diagnosis of Sjögren's Syndrome: A Place in the Diagnostic Criteria?. *Rheumatic Disease Clinics of North America*, **2016**, 42, 501-17 | 2.4 | 20 |
| 69 | Sjögren syndrome. *Nature Reviews Disease Primers*, **2016**, 2, 16047 | 51.1 | 267 |
| 68 | Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. *Rheumatology*, **2016**, 55, 789-800 | 3.9 | 84 |
| 67 | Asthma Control and Airway Inflammation in Patients with Eosinophilic Granulomatosis with Polyangiitis. *Journal of Allergy and Clinical Immunology: in Practice*, **2016**, 4, 512-9 | 5.4 | 12 |
| 66 | Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. *Expert Review of Clinical Immunology*, **2016**, 12, 137-56 | 5.1 | 83 |
| 65 | Classification Criteria of Sjögren's Syndrome. *Rare Diseases of the Immune System*, **2016**, 267-278 | 0.2 | |
| 64 | Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. *Laryngoscope*, **2016**, 126, 2792-2797 | 3.6 | 19 |

| | | | |
|---|---|---|---|
| 63 | The Need to Target Mucosa-Associated Lymphoid Tissue for Preventing Lymphoma in Rheumatoid Factor-Positive Patients With Sjögren's Syndrome: Comment on the Article by Nocturne et al. *Arthritis and Rheumatology*, **2016**, 68, 1318-9 | 9.5 | 3 |
| 62 | One year in review 2016: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2016**, 34, 161-71 | 2.2 | 20 |
| 61 | One year in review: systemic vasculitis. *Clinical and Experimental Rheumatology*, **2016**, 34, S1-6 | 2.2 | 9 |
| 60 | One year in review 2016: idiopathic inflammatory myopathies. *Clinical and Experimental Rheumatology*, **2016**, 34, 966-974 | 2.2 | 6 |
| 59 | Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjögren's syndrome from undifferentiated connective tissue diseases. *Rheumatology*, **2015**, 54, 2198-204 | 3.9 | 18 |
| 58 | Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. *Autoimmunity Reviews*, **2015**, 14, 1019-22 | 13.6 | 56 |
| 57 | Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. *European Journal of Internal Medicine*, **2015**, 26, 545-53 | 3.9 | 254 |
| 56 | A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. *Lupus*, **2015**, 24, 315-20 | 2.6 | 55 |
| 55 | Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. *Scandinavian Journal of Rheumatology*, **2015**, 44, 36-41 | 1.9 | 38 |
| 54 | Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. *Arthritis Research and Therapy*, **2015**, 17, 277 | 5.7 | 46 |
| 53 | Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. *Journal of Internal Medicine*, **2015**, 278, 185-92 | 10.8 | 71 |
| 52 | Salivary gland ultrasonography: a highly specific tool for the early diagnosis of primary Sjögren's syndrome. *Arthritis Research and Therapy*, **2015**, 17, 146 | 5.7 | 71 |
| 51 | TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review. *Modern Rheumatology*, **2015**, 25, 642-5 | 3.3 | 13 |
| 50 | In vivo confocal scanning laser microscopy in patients with primary Sjögren's syndrome: A monocentric experience. *Modern Rheumatology*, **2015**, 25, 585-9 | 3.3 | 11 |
| 49 | One year in review 2015: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2015**, 33, 259-71 | 2.2 | 27 |
| 48 | Myositis in primary Sjögren's syndrome: data from a multicentre cohort. *Clinical and Experimental Rheumatology*, **2015**, 33, 457-64 | 2.2 | 26 |
| 47 | One year in review 2015: idiopathic inflammatory myopathies. *Clinical and Experimental Rheumatology*, **2015**, 33, 593-601 | 2.2 | 1 |
| 46 | Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. *Rheumatology*, **2014**, 53, 839-44 | 3.9 | 129 |

| | | | |
|---|---|---|---|
| 45 | The diagnosis and classification of mixed connective tissue disease. *Journal of Autoimmunity*, **2014**, 48-49, 46-9 | 15.5 | 72 |
| 44 | Vitamin D in "early" primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?. *Rheumatology International*, **2014**, 34, 1159-64 | 3.6 | 23 |
| 43 | The classification criteria for Sjögren syndrome: issues for their improvement from the study of a large Italian cohort of patients. *Annals of the Rheumatic Diseases*, **2014**, 73, e35 | 2.4 | 6 |
| 42 | Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. *Journal of Autoimmunity*, **2014**, 51, 75-80 | 15.5 | 97 |
| 41 | Pain in Sjögren's syndrome. *Reumatismo*, **2014**, 66, 39-43 | 1.1 | 5 |
| 40 | Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity. *Clinical Rheumatology*, **2013**, 32, 1071-3 | 3.9 | 21 |
| 39 | Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. *Autoimmunity Reviews*, **2013**, 12, 537-41 | 13.6 | 64 |
| 38 | Outcome of pregnancy in Italian patients with primary Sjögren syndrome. *Journal of Rheumatology*, **2013**, 40, 1143-7 | 4.1 | 22 |
| 37 | Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study. *Clinical Rheumatology*, **2013**, 32, 1547-8 | 3.9 | 7 |
| 36 | Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. *Rheumatology*, **2013**, 52, 1387-96 | 3.9 | 46 |
| 35 | The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome. *Journal of Internal Medicine*, **2013**, 274, 480-9 | 10.8 | 60 |
| 34 | Occurrence of Hashimoto thyroiditis among the first- and second-degree relatives of systemic lupus erythematosus patients with Hashimoto thyroiditis. *Reumatismo*, **2013**, 65, 203-4 | 1.1 | |
| 33 | Analysis of the evolution of UCTD to defined CTD after a long term follow-up. *Clinical and Experimental Rheumatology*, **2013**, 31, 471 | 2.2 | 13 |
| 32 | Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. *Clinical and Experimental Rheumatology*, **2013**, 31, 272-80 | 2.2 | 30 |
| 31 | A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis. *Rheumatology International*, **2012**, 32, 349-56 | 3.6 | 5 |
| 30 | Classification criteria for Sjogren's syndrome: a critical review. *Journal of Autoimmunity*, **2012**, 39, 9-14 | 15.5 | 95 |
| 29 | A clinical prediction rule for lymphoma development in primary Sjögren's syndrome. *Journal of Rheumatology*, **2012**, 39, 804-8 | 4.1 | 41 |
| 28 | Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. *Clinical and Experimental Rheumatology*, **2012**, 30, S130-8 | 2.2 | 10 |

| | | | |
|---|---|---|---|
| 27 | Emerging trends in Sjögren's syndrome: basic and translational research. *Clinical and Experimental Rheumatology*, **2012**, 30, 779-84 | 2.2 | 13 |
| 26 | Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2012**, 30, 785-90 | 2.2 | 24 |
| 25 | Future prospects for salivary proteomics in rheumatology: the example of eosinophil granulomatosis with polyangiitis. *Clinical and Experimental Rheumatology*, **2012**, 30, 810-1 | 2.2 | 2 |
| 24 | Ocular Surface Disease Index (OSDI): a potential useful instrument for the assessment of vision-targeted health-related quality of life (VT-HRQ) in primary Sjögren's syndrome (pSS) clinical trials?. *Clinical and Experimental Rheumatology*, **2012**, 30, 812-3 | 2.2 | 5 |
| 23 | Minor salivary gland biopsy and Sjögren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers. *Clinical and Experimental Rheumatology*, **2012**, 30, 929-33 | 2.2 | 15 |
| 22 | Correspondence between salivary proteomic pattern and clinical course in primary Sjögren syndrome and non-Hodgkin's lymphoma: a case report. *Journal of Translational Medicine*, **2011**, 9, 188 | 8.5 | 16 |
| 21 | Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. *Arthritis Research and Therapy*, **2011**, 13, R194 | 5.7 | 78 |
| 20 | Classification Criteria **2011**, 417-428 | | |
| 19 | Current Concepts on Classification Criteria and Disease Status Indexes in Sjögren's Syndrome **2011**, 59-72 | | |
| 18 | Clinical manifestations and treatment of Churg-Strauss syndrome. *Rheumatic Disease Clinics of North America*, **2010**, 36, 527-43 | 2.4 | 66 |
| 17 | Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis?. *Proteomics - Clinical Applications*, **2010**, 4, 315-24 | 3.1 | 32 |
| 16 | Detection of potential markers of primary fibromyalgia syndrome in human saliva. *Proteomics - Clinical Applications*, **2009**, 3, 1296-304 | 3.1 | 24 |
| 15 | Proteomic analysis of the saliva: a clue for understanding primary from secondary Sjögren's syndrome?. *Autoimmunity Reviews*, **2008**, 7, 185-91 | 13.6 | 45 |
| 14 | Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. *Annals of the Rheumatic Diseases*, **2008**, 67, 80-3 | 2.4 | 14 |
| 13 | Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews. *Clinical Rheumatology*, **2008**, 27, 1045-8 | 3.9 | 9 |
| 12 | Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: is its presence in whole saliva a potential predictor of pulmonary involvement?. *Journal of Rheumatology*, **2008**, 35, 1820-4 | 4.1 | 18 |
| 11 | Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. *Arthritis and Rheumatism*, **2007**, 56, 2223-31 | | 145 |
| 10 | Proteome analysis of whole saliva: a new tool for rheumatic diseases--the example of Sjögren's syndrome. *Proteomics*, **2007**, 7, 1634-43 | 4.8 | 117 |

| | | | |
|---|---|---|---|
| 9 | Proteomic diagnosis of Sjögren's syndrome. *Expert Review of Proteomics*, **2007**, 4, 757-67 | 4.2 | 31 |
| 8 | LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 873-9 | 4 | 12 |
| 7 | Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. *Journal of Rheumatology*, **2007**, 34, 2063-9 | 4.1 | 36 |
| 6 | Undifferentiated connective tissue diseases (UCTD). *Autoimmunity Reviews*, **2006**, 6, 1-4 | 13.6 | 85 |
| 5 | Mucocutaneous Manifestations of Sjogren's Syndrome. *Handbook of Systemic Autoimmune Diseases*, **2006**, 5, 147-160 | 0.3 | 2 |
| 4 | Anti-Sm and anti-RNP antibodies. *Autoimmunity*, **2005**, 38, 47-54 | 3 | 158 |
| 3 | Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. *Rheumatology*, **2005**, 44, 1074-5 | 3.9 | 47 |
| 2 | Treatment of chronic hepatitis C infection with cryoglobulinemia. *Current Opinion in Rheumatology*, **2002**, 14, 231-7 | 5.3 | 10 |
| 1 | Unusual concomitant small- and large-fiber neuropathy related to hypereosinophilic syndrome. *Clinical and Experimental Neuroimmunology*, | 0.4 | |